Privacy policy

Our website uses cookies to enhance your online experience by; measuring audience engagement, analyzing how our webpage is used, improving website functionality, and delivering relevant, personalized marketing content.
Your privacy is important to us. Thus, you have full control over your cookie preferences and can manage which ones to enable. You can find more information about cookies in our Cookie Policy, about the types of cookies we use on Atos Cookie Table, and information on how to withdraw your consent in our Privacy Policy.

Our website uses cookies to enhance your online experience by; measuring audience engagement, analyzing how our webpage is used, improving website functionality, and delivering relevant, personalized marketing content. Your privacy is important to us. Thus, you have full control over your cookie preferences and can manage which ones to enable. You can find more information about cookies in our Cookie Policy, about the types of cookies we use on Atos Cookie Table, and information on how to withdraw your consent in our Privacy Policy.

Skip to main content

Digitizing pharmaceutical manufacturing methods

Streamlining pharmaceutical manufacturing with the power of enterprise architecture with CPI


At a glance

Atos partnered with CPI to develop industry-endorsed architectural blueprints to help pharmaceutical manufacturers integrate new practices with minimal risk. This will enable more agile, efficient and personalized medicine manufacturing.


Outcomes

  • A repository of validated blueprints addressing key industry challenges.
  • Including a complete architectural stack, capability modeling, end-to-end processes, application views and data integration schemas.
  • Reducing the risk of new manufacturing processes and saving time and resources by avoiding lengthy planning.

Atos has been a key partner in helping us develop reliable, reusable architectural blueprints. The team’s expertise and agile approach have enabled us to drive innovations in pharma manufacturing while minimizing the risk for industry leaders.

Martin Keane
Head of Digital Innovation
CPI

Client Challenge

For many years, the pharmaceutical industry has relied on traditional batch manufacturing methods. However, the shift from standardized treatment to more personalized medicine means the industry must adopt new technologies and practices. This transition aims to develop more targeted therapies, producing smaller batch sizes and ultimately moving towards a more continuous manufacturing methodology. Although, trialing new methods is complex and can be seen as high risk, especially in an industry that is inherently risk-sensitive. This is where CPI can help.

CPI operates the Medicines Manufacturing Innovation Centre, which serves as a catalyst for innovation. At the Centre, pharmaceutical companies can safely test and refine innovative manufacturing processes without disrupting their operations. To accelerate industry-wide adoption, CPI sought to develop architectural blueprints that could be easily shared with pharmaceutical companies, allowing them to integrate new practices into their operations with minimal risk.

Solution

Atos formed a core architecture team to work closely with the team at the Medicines Manufacturing Innovation Centre and its Digital Membership which included global pharmaceutical companies, leading tech firms, and academic bodies. The overall goal was to develop reusable technology-agnostic architectural blueprints to address key industry challenges and promote advancements in manufacturing.

When Atos was approached to support the project, it was at risk of being too technology-led. The architectures needed to be reusable without being tied to a specific technology, so we developed an enterprise architectural process applying the open group architecture framework (TOGAF). We assessed the current state of pharmaceutical manufacturing, worked with the Digital Membership to understand the desired future states and identified the capabilities required to bridge the gap. Additionally, we also highlighted the cost of not achieving the desired future state.

Our approach was agile, involving sprints toward various goals. We continuously collaborated with the core team at CPI while scheduling face-to-face meetings every six weeks with the broader membership to review progress and establish new sprint goals for the next interval. A key challenge was balancing progress with the core team against prioritizing the wider membership, but a unique aspect of our model was being able to successfully reach a consensus on the blueprinting requirements, even amongst conflicting interests.

Business Benefits

In partnership with Digital Membership, we developed a comprehensive repository of validated blueprints to address real industry challenges such as sustainability, real-time release, personalized medicine, digital twins and optimized material flow. These blueprints are available to everyone in the Digital Membership and include a complete architectural stack, capability modeling, end-to-end processes, application views and data integration schemas.

Endorsed by industry leaders from the Digital Membership, the blueprints are a valuable accelerator for companies looking to embrace new practices. Any pharmaceutical manufacturing company could easily adopt and implement them, avoiding lengthy planning phases and significantly reducing the risks of implementing new manufacturing processes. Ultimately, this approach will lead to more proven, efficient and agile manufacturing environments, reducing risk and saving significant time and resources.

Why Atos

Atos is a global leader in providing innovative digital solutions with extensive experience in the healthcare sector. We offer transformation capabilities and services to help clients accelerate digitalization in their industries.